Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors
暂无分享,去创建一个
T. Flotte | T. Daly | N. Muzyczka | T. Flotte | M. Sands | M. Campbell-Thompson | N Muzyczka | A Donsante | C Vogler | JM Crawford | J Barker | T Flotte | M Campbell-Thompson | T Daly | MS Sands | C. Vogler | A. Donsante | T. Daly | J. Barker | James M. Crawford | J. Crawford | Thomas M. Daly | Sands
[1] R. Samulski,et al. AAV vectors: is clinical success on the horizon? , 2000, Gene Therapy.
[2] Yamamura Ken-ichi,et al. Efficient selection for high-expression transfectants with a novel eukaryotic vector , 1991 .
[3] N. Munshi,et al. Differential expression in human cells from the p6 promoter of human parvovirus B19 following plasmid transfection and recombinant adeno-associated virus 2 (AAV) infection: human megakaryocytic leukaemia cells are non-permissive for AAV infection. , 1996, The Journal of general virology.
[4] T. Flotte,et al. In vivo model of adeno-associated virus vector persistence and rescue , 1996, Journal of virology.
[5] W. Sly,et al. Treatment of murine mucopolysaccharidosis type VII by syngeneic bone marrow transplantation in neonates. , 1993, Laboratory investigation; a journal of technical methods and pathology.
[6] W. Sly,et al. Syngeneic bone marrow transplantation reduces the hearing loss associated with murine mucopolysaccharidosis type VII. , 1995, Blood.
[7] M. Davisson,et al. Murine mucopolysaccharidosis type VII. Characterization of a mouse with beta-glucuronidase deficiency. , 1989, The Journal of clinical investigation.
[8] W. Sly,et al. Enzyme Replacement with Recombinant β-Glucuronidase in Murine Mucopolysaccharidosis Type VII: Impact of Therapy during the First Six Weeks of Life on Subsequent Lysosomal Storage, Growth, and Survival , 1996, Pediatric Research.
[9] T. Daly,et al. Neonatal intramuscular injection with recombinant adeno-associated virus results in prolonged beta-glucuronidase expression in situ and correction of liver pathology in mucopolysaccharidosis type VII mice. , 1999, Human gene therapy.
[10] P. Laipis,et al. Stable therapeutic serum levels of human alpha-1 antitrypsin (AAT) after portal vein injection of recombinant adeno-associated virus (rAAV) vectors , 2001, Gene Therapy.
[11] M. Sands,et al. Prevention of systemic clinical disease in MPS VII mice following AAV-mediated neonatal gene transfer , 2001, Gene Therapy.
[12] T. Flotte,et al. Recombinant adeno-associated virus (AAV-CFTR) vectors do not integrate in a site-specific fashion in an immortalized epithelial cell line. , 1996, Gene therapy.
[13] H. Niwa,et al. Efficient selection for high-expression transfectants with a novel eukaryotic vector. , 1991, Gene.
[14] B. Byrne,et al. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield , 1999, Gene Therapy.
[15] T. Flotte,et al. Adeno-associated virus vector gene expression occurs in nondividing cells in the absence of vector DNA integration. , 1994, American journal of respiratory cell and molecular biology.
[16] W. Sly,et al. Murine mucopolysaccharidosis type VII: long term therapeutic effects of enzyme replacement and enzyme replacement followed by bone marrow transplantation. , 1997, The Journal of clinical investigation.
[17] W. Sly,et al. Increased life span and correction of metabolic defects in murine mucopolysaccharidosis type VII after syngeneic bone marrow transplantation. , 1991, Blood.